Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03509012 · ClinicalTrials.gov registry record · Phase 1

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
105
Enrollment target

NCT03509012: Completed Phase 1 study, sponsored by AstraZeneca.

NCT03509012 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 105 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03509012, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
105 participants
Enrollment target

Study Summary

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors

Interventions

  • DRUG Durvalumab
  • DRUG Tremelimumab
  • DRUG Cisplatin (dose level 4)
  • DRUG Cisplatin (dose level 3)
  • DRUG Carboplatin (dose level 1)

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2018-05-02
Est. Completion 2025-01-08
Phase Phase 1
AstraZeneca

1,285 total trials

What the finished NCT03509012 record still lists

NCT03509012 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher).

The record links to 0 conditions, and to 5 interventions - of which Durvalumab is the first listed.

NCT03509012 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03509012 about?

NCT03509012 is a clinical study titled "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors". This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors

What is the current status of trial NCT03509012?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2018-05-02. Estimated completion is 2025-01-08.

What interventions are being tested in trial NCT03509012?

The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Cisplatin (dose level 4) (DRUG), Cisplatin (dose level 3) (DRUG), Carboplatin (dose level 1) (DRUG).

Who is sponsoring clinical trial NCT03509012?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03509012's enrollment target sits among peer trials

105 533rd of 2000 higher than 1,465 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03509012, the US trial registry maintained by the National Library of Medicine. NCT03509012 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.